LU91162I2 - Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables. - Google Patents

Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables.

Info

Publication number: LU91162I2
Authority: LU; Luxembourg
Prior art keywords: alkyl; amino; alkoxy; halogen; optionally substituted
Prior art date: 1989-11-28

Application number

LU91162C

Other languages

English (en)

Original Assignee

Roche Palo Alto Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-28

Filing date

2005-04-18

Publication date

2005-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23755479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91162(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-18 Application filed by Roche Palo Alto Llc filed Critical Roche Palo Alto Llc

2005-06-20 Publication of LU91162I2 publication Critical patent/LU91162I2/fr

Links

125000000217 alkyl group Chemical group 0.000 abstract 6
125000003545 alkoxy group Chemical group 0.000 abstract 3
229910052736 halogen Inorganic materials 0.000 abstract 3
150000002367 halogens Chemical class 0.000 abstract 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
-1 nitro, amino, amino carbonyl Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000000168 pyrrolyl group Chemical group 0.000 abstract 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

LU91162C 1989-11-28 2005-04-18 Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables. LU91162I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US44208289A	1989-11-28	1989-11-28

Publications (1)

Publication Number	Publication Date
LU91162I2 true LU91162I2 (fr)	2005-06-20

Family

ID=23755479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91162C LU91162I2 (fr)	1989-11-28	2005-04-18	Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables.

Country Status (23)

Country	Link
US (1)	US5202333A (fr)
EP (1)	EP0430190B1 (fr)
JP (1)	JPH0662607B2 (fr)
KR (1)	KR970007917B1 (fr)
AT (1)	ATE124698T1 (fr)
AU (1)	AU642178B2 (fr)
BR (1)	BR1100680A (fr)
CA (1)	CA2030718C (fr)
DE (2)	DE69020694T2 (fr)
DK (1)	DK0430190T3 (fr)
ES (1)	ES2075121T3 (fr)
FI (1)	FI98367C (fr)
HK (1)	HK36097A (fr)
HU (1)	HU218654B (fr)
IE (1)	IE68434B1 (fr)
IL (2)	IL110622A (fr)
LU (1)	LU91162I2 (fr)
NL (1)	NL300194I1 (fr)
NO (2)	NO175309C (fr)
NZ (1)	NZ236225A (fr)
PL (3)	PL166272B1 (fr)
PT (1)	PT96001B (fr)
ZA (1)	ZA909529B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL166272B1 (pl) *	1989-11-28	1995-04-28	Syntex Inc	Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5491148A (en) *	1991-04-26	1996-02-13	Syntex (U.S.A.) Inc.	Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
EP1082959A1 (fr)	1991-09-20	2001-03-14	Glaxo Group Limited	Utilisation des NK1-antagonistes pour le traitement de la depression
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
CZ286632B6 (cs) *	1992-09-29	2000-05-17	Inhale Therapeutic Systems	Farmaceutický prostředek
EP1462096B1 (fr) *	1994-03-07	2008-12-10	Nektar Therapeutics	Methodes et compositions pour la délivrance pulmonale d'insulin
US20030113273A1 (en) *	1996-06-17	2003-06-19	Patton John S.	Methods and compositions for pulmonary delivery of insulin
GB2288732B (en) *	1994-04-13	1998-04-29	Quadrant Holdings Cambridge	Pharmaceutical compositions
CN1073119C (zh) *	1994-05-18	2001-10-17	吸入治疗系统公司	干扰素干粉配方的方法及组合物
US5567818A (en) *	1994-07-08	1996-10-22	Syntex (U.S.A.) Inc.	Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
US5510486A (en) *	1994-07-26	1996-04-23	Syntex (U.S.A.) Inc.	Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5492914A (en) *	1994-07-28	1996-02-20	Syntex (U.S.A.) Inc.	2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
US6290991B1 (en) *	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US5723103A (en) *	1994-12-09	1998-03-03	Vanderbilt University	Substituted benzamides and radioligand analogs and methods of use
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
ATE434437T1 (de) *	1999-02-18	2009-07-15	Novasearch Ag	Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
DK1280520T4 (en)	2000-05-10	2018-06-25	Novartis Ag	Phospholipid based powders for drug delivery
US7871598B1 (en) *	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20050042194A1 (en)	2000-05-11	2005-02-24	A.P. Pharma, Inc.	Semi-solid delivery vehicle and pharmaceutical compositions
JP2003533482A (ja) *	2000-05-18	2003-11-11	グラクソグループリミテッド	機能性消化不良の治療方法
CA2438641A1 (fr)	2001-02-15	2002-08-22	King Pharmaceuticals, Inc.	Compositions pharmaceutiques stabilisees, compositions d'hormone de thyroide et technique de preparation
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
WO2003053411A1 (fr)	2001-12-19	2003-07-03	Nektar Therapeutics	Administration pulmonaire d'aminoglycosides
US7001900B2 (en)	2002-02-20	2006-02-21	Pfizer Inc.	Azabicyclic compounds for the treatment of disease
US20030187017A1 (en) *	2002-11-14	2003-10-02	Mangel Allen Wayne	Method for treating functional dyspepsia
AU2003302072A1 (en) *	2002-11-15	2004-06-15	Helsinn Healthcare Sa	Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en)	2003-01-30	2013-12-03	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) *	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) *	2003-02-18	2012-01-11	Helsinn Healthcare Sa	Uses of palonosetron hydrochloride
US20060167072A1 (en) *	2004-01-30	2006-07-27	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
CN100336508C (zh) *	2005-02-23	2007-09-12	重庆医药工业研究院有限责任公司	一种稳定的帕洛诺司琼注射液
US20070031342A1 (en) *	2005-06-22	2007-02-08	Nektar Therapeutics	Sustained release microparticles for pulmonary delivery
US20080004260A1 (en) *	2006-06-29	2008-01-03	Transcept Pharmaceuticals, Inc.	Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8614225B2 (en) *	2006-08-30	2013-12-24	Dr. Reddy's Laboratories Limited	Process for the purification of palonosetron or its salt
EP2103612A1 (fr)	2006-10-23	2009-09-23	Sicor, Inc.	Formules cristallines d'hydrochlorure de palonosétron
ATE427742T1 (de) *	2006-10-24	2009-04-15	Helsinn Healthcare Sa	Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilitat und bioverfugbarkeit
JP2010512333A (ja) *	2006-12-07	2010-04-22	ヘルシンヘルスケアソシエテアノニム	塩酸パロノセトロンの結晶及び非晶質形
US8334388B2 (en) *	2007-05-29	2012-12-18	Chemagis Ltd.	Palonosetron salts and processes for preparation and purification thereof
US20090227623A1 (en) *	2007-09-15	2009-09-10	Protia, Llc	Deuterium-enriched palosetron
CN101157691B (zh) *	2007-10-18	2011-01-12	杭州九源基因工程有限公司	一种盐酸帕洛诺司琼的生产工艺
AR069625A1 (es)	2007-12-13	2010-02-03	Glenmark Generics Ltd	Base libre de palonosetron y procedimiento para su preparacion
WO2009087643A1 (fr) *	2008-01-11	2009-07-16	Natco Pharma Limited	Nouvelles formes cristallines du chlorhydrate de palonosétron
WO2009136405A1 (fr) *	2008-05-05	2009-11-12	Natco Pharma Limited	Palonosétron de pureté élevée et ses caractéristiques à l’état solide
US20100048607A1 (en) *	2008-08-25	2010-02-25	Chandrashekhar Kocherlakota	Formulations comprising palonosetron
US20100099701A1 (en) *	2008-10-20	2010-04-22	Auspex Pharmaceuticals, Inc.	Isoquinolinone modulators of 5-ht3 receptors
EP2364312A4 (fr) *	2008-11-11	2012-05-02	Reddys Lab Ltd Dr	Synthèse de chlorhydrate de palonosétron cristallin
EP2364138A2 (fr) *	2008-12-08	2011-09-14	Teva Pharmaceutical Industries Ltd.	Formulation de palonosétron
AU2009324545A1 (en) *	2008-12-11	2011-06-30	A.P. Pharma, Inc.	Methods for enhancing stability of polyorthoesters and their formulations
CN101851233B (zh) *	2009-04-03	2013-03-06	四川滇虹医药开发有限公司	盐酸帕洛诺司琼和其前体化合物及制备
CN101849904A (zh) *	2009-04-03	2010-10-06	南京长澳医药科技有限公司	一种帕洛诺司琼注射液及其制备方法
US20100298397A1 (en) *	2009-05-19	2010-11-25	Singh Nikhilesh N	Method of treatment of obsessive compulsive disorder with ondansetron
HUE037300T2 (hu)	2009-05-20	2018-08-28	Inst Nat Sante Rech Med	Szerotonin 5-HT3 receptor antagonisták lezionális vesztibuláris zavarok kezelésében való felhasználásra
ES2432618T3 (es)	2009-05-20	2013-12-04	Inserm (Institut National De La Santé Et De La Recherche Medicale)	Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
EP2448936A2 (fr)	2009-06-30	2012-05-09	Ranbaxy Laboratories Limited	Procédés de préparation des formes i et ii de l'hydrochlorure de palonosétron
CN102510862A (zh)	2009-07-14	2012-06-20	阿尔巴尼分子研究公司	5-ht3受体调节剂、其制备方法和用途
WO2011013095A1 (fr)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Procédés de préparation du palonosétron
EP2499137A1 (fr) *	2009-11-13	2012-09-19	Helsinn Healthcare S.A.	Metabolites de palonosetron
ES2623503T3 (es)	2009-11-18	2017-07-11	Helsinn Healthcare Sa	Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (fr)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions pour traiter les nausées et vomissements à médiation centrale
WO2013057554A2 (fr)	2011-10-18	2013-04-25	Helsinn Healthcare Sa	Combinaisons thérapeutiques de nétupitant et de palonosétron
CN102688185B (zh) *	2012-06-01	2013-07-10	齐鲁制药(海南)有限公司	一种稳定的帕洛诺司琼注射液及其制备方法
JP2017504615A (ja) *	2013-12-23	2017-02-09	サムヤンバイオファーマシューティカルズコーポレイション	パロノセトロンを含有する薬学組成物
WO2017044693A1 (fr)	2015-09-11	2017-03-16	Chase Pharmaceuticals Corporation	Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
PT3435980T (pt) *	2016-06-06	2020-02-21	Helsinn Healthcare Sa	Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
US20200375957A1 (en)	2017-04-24	2020-12-03	Chase Therapeutics Corporation	Compositions and method for treating depression
EP3672964A4 (fr)	2017-08-21	2021-05-26	Leiutis Pharmaceuticals Pvt. Ltd.	Nouvelles formulations à triple combinaison pour une thérapie antiémétique
EP4385500A1 (fr)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Combinaison de doses fixes comprenant du nétupitant et du palonosétron
EP4385497A1 (fr)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Combinaison de doses fixes sans antioxydant de nétupitant et de palonosétron
KR20250125376A (ko)	2022-12-12	2025-08-21	알프레드 이. 티펜바흐어 게엠베하 운트 ＆ 코. 카게	네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제
WO2024126408A1 (fr)	2022-12-12	2024-06-20	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Association de dose fixe sans antioxydant de netupitant et de palonosétron

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3341528A (en) *	1963-11-07	1967-09-12	Warner Lambert Pharmaceutical	Substituted benzoquinolines
US3896132A (en) *	1969-08-19	1975-07-22	Hoffmann La Roche	Process for preparing 1,2,3,8,9,9a-hexahydro-5,6-dialkoxy-1-alkyl-benzo(d,e)quinolin-7-ore compounds
US4309543A (en) *	1980-03-17	1982-01-05	Dynapol	Process for preparing cyclic amides
EP0093488A3 (fr) *	1982-03-18	1984-05-23	Beecham Group Plc	Composés nortropyl benzopyrrolinoniques, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4571396A (en) *	1984-04-16	1986-02-18	Warner-Lambert Company	Antibacterial agents
AU8325987A (en) *	1986-12-11	1988-06-30	Upjohn Company, The	Antipsychotic amino-polyhydro-benz-(iso)quinolines and intermediates
ATE108791T1 (de) *	1987-11-04	1994-08-15	Beecham Group Plc	Neue 4-oxobenzotriazine und 4-oxochinazoline.
PL166272B1 (pl) *	1989-11-28	1995-04-28	Syntex Inc	Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
AU7618991A (en) *	1990-05-14	1991-11-14	Syntex (U.S.A.) Inc.	Novel tricyclic compounds
US5189041A (en) *	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists

1990
- 1990-11-27 PL PL90287961A patent/PL166272B1/pl unknown
- 1990-11-27 ZA ZA909529A patent/ZA909529B/xx unknown
- 1990-11-27 DE DE69020694T patent/DE69020694T2/de not_active Expired - Lifetime
- 1990-11-27 ES ES90122689T patent/ES2075121T3/es not_active Expired - Lifetime
- 1990-11-27 PT PT96001A patent/PT96001B/pt not_active IP Right Cessation
- 1990-11-27 IL IL11062290A patent/IL110622A/en not_active IP Right Cessation
- 1990-11-27 DE DE200512000027 patent/DE122005000027I2/de active Active
- 1990-11-27 IL IL9648690A patent/IL96486A/en active Protection Beyond IP Right Term
- 1990-11-27 JP JP2328764A patent/JPH0662607B2/ja not_active Expired - Fee Related
- 1990-11-27 AU AU66963/90A patent/AU642178B2/en not_active Expired
- 1990-11-27 IE IE426990A patent/IE68434B1/en not_active IP Right Cessation
- 1990-11-27 DK DK90122689.4T patent/DK0430190T3/da active
- 1990-11-27 PL PL90303660A patent/PL166267B1/pl unknown
- 1990-11-27 HU HU670/90A patent/HU218654B/hu active Protection Beyond IP Right Term
- 1990-11-27 NO NO905120A patent/NO175309C/no not_active IP Right Cessation
- 1990-11-27 CA CA002030718A patent/CA2030718C/fr not_active Expired - Lifetime
- 1990-11-27 PL PL90303661A patent/PL166277B1/pl unknown
- 1990-11-27 EP EP90122689A patent/EP0430190B1/fr not_active Expired - Lifetime
- 1990-11-27 AT AT90122689T patent/ATE124698T1/de active
- 1990-11-27 KR KR1019900019275A patent/KR970007917B1/ko not_active Expired - Lifetime
- 1990-11-27 NZ NZ236225A patent/NZ236225A/en unknown
- 1990-11-27 FI FI905839A patent/FI98367C/fi active Protection Beyond IP Right Term
1991
- 1991-05-22 US US07/704,565 patent/US5202333A/en not_active Expired - Lifetime
1997
- 1997-03-20 HK HK36097A patent/HK36097A/en not_active IP Right Cessation
- 1997-05-08 BR BR1100680-3A patent/BR1100680A/pt active IP Right Grant
2005
- 2005-04-18 LU LU91162C patent/LU91162I2/fr unknown
- 2005-04-20 NL NL300194C patent/NL300194I1/nl unknown
- 2005-09-21 NO NO2005023C patent/NO2005023I2/no unknown

Also Published As

Publication number	Publication date
ATE124698T1 (de)	1995-07-15
IE68434B1 (en)	1996-06-12
DE122005000027I1 (de)	2005-08-04
ZA909529B (en)	1992-08-26
KR970007917B1 (ko)	1997-05-17
PL287961A1 (en)	1991-12-02
CA2030718A1 (fr)	1991-05-29
PL166272B1 (pl)	1995-04-28
DE69020694D1 (de)	1995-08-10
JPH0662607B2 (ja)	1994-08-17
NL300194I2 (nl)	2005-07-01
EP0430190A3 (en)	1992-01-22
FI905839L (fi)	1991-05-29
NO905120L (no)	1991-05-29
EP0430190B1 (fr)	1995-07-05
HUT56368A (en)	1991-08-28
AU642178B2 (en)	1993-10-14
NO175309B (no)	1994-06-20
HK36097A (en)	1997-03-27
PT96001B (pt)	1998-01-30
DE122005000027I2 (de)	2006-03-16
IL96486A (en)	1995-03-30
PT96001A (pt)	1991-09-30
ES2075121T3 (es)	1995-10-01
JPH03176486A (ja)	1991-07-31
NO905120D0 (no)	1990-11-27
NO2005023I2 (no)	2009-10-05
IL110622A (en)	1995-03-30
FI98367B (fi)	1997-02-28
FI905839A0 (fi)	1990-11-27
HU218654B (hu)	2000-10-28
DK0430190T3 (da)	1995-08-21
PL166277B1 (pl)	1995-04-28
IE904269A1 (en)	1991-06-05
PL166267B1 (pl)	1995-04-28
AU6696390A (en)	1991-06-06
CA2030718C (fr)	1998-05-12
EP0430190A2 (fr)	1991-06-05
HU907660D0 (en)	1991-06-28
IL96486A0 (en)	1991-08-16
US5202333A (en)	1993-04-13
DE69020694T2 (de)	1996-01-18
NO175309C (no)	1994-09-28
FI98367C (fi)	1997-06-10
NZ236225A (en)	1992-09-25
KR910009699A (ko)	1991-06-28
NO2005023I1 (no)	2005-10-03
NL300194I1 (nl)	2005-07-01
BR1100680A (pt)	2000-02-08

Publication	Publication Date	Title
LU91162I2 (fr)	2005-06-20	Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables.
EA200100553A1 (ru)	2001-12-24	Замещенные бициклические производные, полезные в качестве противораковых агентов
KR900012911A (ko)	1990-09-03	흥분성 아미노산 수용기 길항질 화합물
EA200000731A1 (ru)	2001-02-26	Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
ATE219766T1 (de)	2002-07-15	N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
ATE297203T1 (de)	2005-06-15	Antithrombotische mitteln
EA200200873A1 (ru)	2003-04-24	Новые пиперазиновые производные
ATE306261T1 (de)	2005-10-15	Antithrombosemittel
EA200000391A1 (ru)	2000-12-25	Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
ES2124545T3 (es)	1999-02-01	Azolidindionas como agentes antihiperglucemicos.
EA199800794A1 (ru)	1999-04-29	Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
TR199801782T2 (xx)	1998-12-21	Kinoksalindionlar
PT1057827E (pt)	2003-11-28	Derivados da espiropiperidina
EP0604352A3 (fr)	1995-02-08	Composés hétérocycliques substitués par un groupement aryle.
EP0604355A3 (fr)	1995-02-08	Composés hétérocycliques substitués par un groupement alkyle.
TW334428B (en)	1998-06-21	Novel benzodiazepine derivatives
DE69402703D1 (de)	1997-05-22	3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND
EA200101050A1 (ru)	2002-04-25	Замещенные бензолактамные соединения
WO1997029077A1 (fr)	1997-08-14	Derives amides substitues
DE60009932D1 (de)	2004-05-19	5-aminoalkyl- und 5-aminocarbonylsubstituierte indole